Despite recent tightening of cutoffs for hypertension (HT) in major global guidelines, guidelines, especially according to GTS, remain debatable. We analyzed data from a nationwide claims database on 293,396 participants without prior CAD or CVD from 2008-16. Multivariate Cox regression model identified risks of CAD and CVD events. Hazard ratios (HRs) were compared among 5 levels of systolic blood pressure (SBP) (≤119, 120-129, 130-139, 140-149, ≥150) according to GTS [i.e., normal glucose tolerance (NGT), prediabetes (pre-DM), diabetes (DM)]. During the study period, 1099 CAD and 1990 CVD events occurred. Those with SBP levels ≥120 mmHg had a significantly higher risk of incident CAD/CVD than those with lower levels. The incidence of CAD and CVD did not differ significantly between NGT and pre-DM in those with SBP ≤119 whereas HRs for incident CAD for DM was almost 2.7, which was similar to NGT and pre-DM with SBP ≥150 mmHg (Table). Compared with NGT and SBP ≤119 mmHg, the HR for incident CAD among DM and SBP ≥150 mmHg was 5.91 (4.22-8.26), while SBP ≥150 mmHg significantly increased the risk of CVD about 4 fold regardless of GTS. These results based on a large database implied the need for even lower BP targets regardless of GTS. The impact of BP was stronger in DM in preventing CAD.


M.H. Yamada: None. K. Fujihara: None. Y. Yaguchi: None. T. Osawa: None. M. Kitazawa: None. Y. Matsubayashi: None. M. Iwanaga: None. T. Yamada: None. N. Yamanaka: None. H. Seida: None. W. Ogawa: Research Support; Self; Astellas Pharma Inc., Boehringer Ingelheim Pharma GmbH & Co.KG, Eli Lilly Japan K.K., Kowa Company, Ltd., Nippon Boehringer Ingelheim Co. Ltd., Novo Nordisk Inc., Ono Pharmaceutical Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd. Other Relationship; Self; Sumitomo Dainippon Pharma Co., Ltd., Takeda Pharmaceutical Company Limited. H. Sone: Research Support; Self; Kyowa Hakko Kirin Co., Ltd., Novartis AG, Ono Pharmaceutical Co., Ltd., Taisho Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co.



Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at